Deep Vein Thrombosis (DVT)

Deep vein thrombosis (DVT) is caused by the formation of venous blood clots in the arms and legs. This page includes information on technologies to treat DVT  using catheter based interventions and thrombolysis. 

News | Cardiovascular Clinical Studies

April 8, 2024 — People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin ...

Home April 08, 2024
News | ACC

March 21, 2024 — Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal ...

Home March 21, 2024
News | Coronavirus (COVID-19)

January 11, 2024 — Acute cardiovascular manifestations of COVID-19, such as heart failure, thrombosis, and dysrhythmia ...

Home January 11, 2024
News | VIVA

October 31, 2022 — Results from the Late-Breaking Clinical Trials session at The VEINS Conference in Las Vegas, NV, were ...

Home October 31, 2022
News | Venous Therapies

October 14, 2022 —  Medtronic, a global leader in medical technology, announced the 36-month final results from the ABRE ...

Home October 14, 2022
A rise in cardiovascular diseases has fueled technological advancements in thrombectomy devices
Feature | Thrombectomy Devices | By Global Market Insights

The global thrombectomy devices market is poised to experience substantial expansion, owing to the emergence of ...

Home June 27, 2022
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Videos | Coronavirus (COVID-19)

Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an ...

Home April 01, 2021
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
News | Thrombectomy Devices

January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...

Home January 08, 2021
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.
Feature | Coronavirus (COVID-19)

December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants ...

Home December 23, 2020
Subscribe Now